Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib

Frontiers in Oncology

Oncology

Weiliang Kong¹  Guo-qiang Hu²  Guo-qiang Song²  Yi-zhong Li³ 

[1] Department of Pathology, Changxing County Hospital of Traditional Chinese Medicine, Huzhou, China;Department of Respiratory, Changxing County Hospital of Traditional Chinese Medicine, Huzhou, China;Department of Respiratory, Changxing County Jiapu Town Health Center, Huzhou, China;

关键词: STRN-ALK;    NSCLC;    ensartinib;    case report;    TKIs;   

DOI  :  10.3389/fonc.2023.1235679

 received in 2023-06-15, accepted in 2023-08-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

Several cases of STRN-ALK fusion have been reported, and some anaplastic lymphoma kinase (ALK) inhibitors have been shown to be effective for treatment. Nevertheless, no cases of COVID-19 leading to heart failure and respiratory failure have been reported in people older than 70 years treated with ALK inhibitors. The present case report describes a 70-year-old patient with usual chronic obstructive pulmonary disease, diabetes, depression, and carotid plaque disease. Next-generation sequencing of tissue obtained by puncture biopsy revealed a STRN-ALK mutation accompanied by a TP53 mutation. The patient was treated with ensartinib and developed COVID-19 leading to heart failure and respiratory failure; nevertheless, he had a good clinical outcome and exhibited high treatment tolerability.

【 授权许可】

Unknown   
Copyright © 2023 Song, Li, Kong and Hu